Dexcom Study in NEJM Shows CGM's Power for Type 2 Diabetes Without Insulin
Event summary
- Dexcom's CONNECT study published in NEJM shows 1.6% A1C reduction in Type 2 diabetes patients not on insulin using Dexcom G7.
- Participants spent 5 additional hours per day in glucose target range vs. routine care.
- 97% of participants continued CGM use after 26 weeks, with benefits observed across diverse demographics.
- GLP-1 therapy users saw additional 0.9% A1C reduction with CGM.
- Study involved 440 participants across 22 US primary care sites.
The big picture
This NEJM publication represents a significant validation of CGM technology for a broader diabetes population, potentially redefining treatment standards. The study's rigorous design and positive outcomes could accelerate adoption in primary care settings, expanding Dexcom's market beyond its traditional Type 1 diabetes focus. The results also highlight the complementary benefits of CGM with GLP-1 therapies, an important growth area in diabetes treatment.
What we're watching
- Market Expansion
- Whether Dexcom can leverage these results to expand CGM adoption among Type 2 diabetes patients not on insulin.
- Regulatory Impact
- How these findings might influence payer policies and insurance coverage for CGMs.
- Competitive Dynamics
- The pace at which competitors will respond with similar clinical evidence for their CGM devices.